765 related articles for article (PubMed ID: 26248355)
1. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.
Chen KH; Huang YT; Liao CH; Sheng WH; Hsueh PR
Antimicrob Agents Chemother; 2015 Oct; 59(10):6262-5. PubMed ID: 26248355
[TBL] [Abstract][Full Text] [Related]
2. Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014.
Pfaller MA; Flamm RK; Jones RN; Farrell DJ; Mendes RE
Antimicrob Agents Chemother; 2016 Sep; 60(9):5393-9. PubMed ID: 27353270
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
Barber KE; Smith JR; Raut A; Rybak MJ
J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China.
Li S; Guo Y; Zhao C; Chen H; Hu B; Chu Y; Zhang Z; Hu Y; Liu Z; Du Y; Gui Q; Ji P; Zeng J; Cao B; Fu Q; Zhang R; Wang Z; Zhuo C; Feng X; Jia W; Jin Y; Xu X; Liao K; Ni Y; Yu Y; Xu X; Hu Z; Lei JE; Yang Q; Wang H
J Med Microbiol; 2016 Oct; 65(10):1215-1224. PubMed ID: 27599998
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
Prokocimer P; Bien P; Deanda C; Pillar CM; Bartizal K
Antimicrob Agents Chemother; 2012 Sep; 56(9):4608-13. PubMed ID: 22687509
[TBL] [Abstract][Full Text] [Related]
6. Tedizolid susceptibility in linezolid- and vancomycin-resistant Enterococcus faecium isolates.
Klupp EM; Both A; Belmar Campos C; Büttner H; König C; Christopeit M; Christner M; Aepfelbacher M; Rohde H
Eur J Clin Microbiol Infect Dis; 2016 Dec; 35(12):1957-1961. PubMed ID: 27525679
[TBL] [Abstract][Full Text] [Related]
7. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
[TBL] [Abstract][Full Text] [Related]
8. In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016.
Karlowsky JA; Hackel MA; Bouchillon SK; Alder J; Sahm DF
Diagn Microbiol Infect Dis; 2017 Oct; 89(2):151-157. PubMed ID: 28793964
[TBL] [Abstract][Full Text] [Related]
9. Determination of Tedizolid susceptibility interpretive criteria for gram-positive pathogens according to clinical and laboratory standards institute guidelines.
Bensaci M; Flanagan S; Sandison T
Diagn Microbiol Infect Dis; 2018 Mar; 90(3):214-220. PubMed ID: 29277464
[TBL] [Abstract][Full Text] [Related]
10. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.
Rybak JM; Marx K; Martin CA
Pharmacotherapy; 2014 Nov; 34(11):1198-208. PubMed ID: 25266820
[TBL] [Abstract][Full Text] [Related]
11. In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria.
Barman TK; Kumar M; Mathur T; Chaira T; Ramkumar G; Kalia V; Rao M; Pandya M; Yadav AS; Das B; Upadhyay DJ; Hamidullah ; Konwar R; Raj VS; Singh H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7134-7145. PubMed ID: 27645240
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tedizolid against methicillin-resistant Staphylococcus aureus and Peptostreptococcus anaerobius in thigh mixed-infection mouse model.
Yamagishi Y; Mikamo H; Kato H; Nishiyama N; Asai N; Koizumi Y; Sakanashi D; Suematsu H; Matsuura K; Hagihara M
J Infect Chemother; 2017 Jun; 23(6):368-373. PubMed ID: 28343752
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
[TBL] [Abstract][Full Text] [Related]
15. In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
Kanayama S; Ikeda F; Okamoto K; Nakajima A; Matsumoto T; Ishii R; Amano A; Matsuzaki K; Matsumoto S
J Infect Chemother; 2016 Oct; 22(10):720-3. PubMed ID: 27091753
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of tedizolid against gram-positive bacteria in patients with skin and skin structure infections and hospital-acquired pneumonia: a Korean multicenter study.
Lee Y; Hong SK; Choi S; Im W; Yong D; Lee K
Ann Lab Med; 2015 Sep; 35(5):523-30. PubMed ID: 26206690
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
Dowzicky MJ
Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid and tedizolid.
Vanegas Múnera JM; Ocampo Ríos AM; Urrego DM; Jiménez Quiceno JN
Braz J Infect Dis; 2017; 21(5):493-499. PubMed ID: 28432878
[TBL] [Abstract][Full Text] [Related]
19. Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe.
Sahm DF; Deane J; Bien PA; Locke JB; Zuill DE; Shaw KJ; Bartizal KF
Diagn Microbiol Infect Dis; 2015 Feb; 81(2):112-8. PubMed ID: 25488274
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China.
Biedenbach DJ; Bouchillon SK; Johnson B; Alder J; Sahm DF
Eur J Clin Microbiol Infect Dis; 2016 Dec; 35(12):1933-1939. PubMed ID: 27677280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
